0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Bevacizumab Generics Market Research Report 2024
Published Date: August 2024
|
Report Code: QYRE-Auto-13I18045
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Bevacizumab Generics Market Research Report 2024
BUY CHAPTERS

Global Bevacizumab Generics Market Research Report 2024

Code: QYRE-Auto-13I18045
Report
August 2024
Pages:92
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Bevacizumab Generics Market

Bevacizumab generics refer to versions of the medication that are bioequivalent to the original brand-name drug,Avastin.Bevacizumab is a medication used in the treatment of various cancers and certain eye diseases,which works by inhibiting vascular endothelial growth factor(VEGF),a protein that promotes the growth of new blood vessels.
The global Bevacizumab Generics market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Bevacizumab Generics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Bevacizumab Generics is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Bevacizumab Generics include Amneal Pharmaceuticals, Amgen, Celltrion Healthcare, Pfizer, Qilu Pharma, Chia Tai Tianqing, Jiangsu Hengrui Pharmaceuticals, Innovent, Bio-Thera Solutions, SinoCellTech, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Bevacizumab Generics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Bevacizumab Generics.
The Bevacizumab Generics market size, estimations, and forecasts are provided in terms of sales volume (K Dose) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Bevacizumab Generics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Bevacizumab Generics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Bevacizumab Generics Market Report

Report Metric Details
Report Name Bevacizumab Generics Market
Segment by Type
  • 100mg per Vial
  • 400mg per Vial
Segment by Application
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Amneal Pharmaceuticals, Amgen, Celltrion Healthcare, Pfizer, Qilu Pharma, Chia Tai Tianqing, Jiangsu Hengrui Pharmaceuticals, Innovent, Bio-Thera Solutions, SinoCellTech, Shanghai Henlius Biotech, Zhejiang Beta Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Bevacizumab Generics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Bevacizumab Generics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Bevacizumab Generics Market report?

Ans: The main players in the Bevacizumab Generics Market are Amneal Pharmaceuticals, Amgen, Celltrion Healthcare, Pfizer, Qilu Pharma, Chia Tai Tianqing, Jiangsu Hengrui Pharmaceuticals, Innovent, Bio-Thera Solutions, SinoCellTech, Shanghai Henlius Biotech, Zhejiang Beta Pharma

What are the Application segmentation covered in the Bevacizumab Generics Market report?

Ans: The Applications covered in the Bevacizumab Generics Market report are Hospital and Clinic, Retail Pharmacies, Other

What are the Type segmentation covered in the Bevacizumab Generics Market report?

Ans: The Types covered in the Bevacizumab Generics Market report are 100mg per Vial, 400mg per Vial

Recommended Reports

Generic Drug Markets

Biosimilars & Anti-VEGF

Cancer Drug Therapies

1 Bevacizumab Generics Market Overview
1.1 Product Definition
1.2 Bevacizumab Generics by Type
1.2.1 Global Bevacizumab Generics Market Value Comparison by Type (2024-2030)
1.2.2 100mg per Vial
1.2.3 400mg per Vial
1.3 Bevacizumab Generics by Application
1.3.1 Global Bevacizumab Generics Market Value by Application (2024-2030)
1.3.2 Hospital and Clinic
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Global Bevacizumab Generics Market Size Estimates and Forecasts
1.4.1 Global Bevacizumab Generics Revenue 2019-2030
1.4.2 Global Bevacizumab Generics Sales 2019-2030
1.4.3 Global Bevacizumab Generics Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Bevacizumab Generics Market Competition by Manufacturers
2.1 Global Bevacizumab Generics Sales Market Share by Manufacturers (2019-2024)
2.2 Global Bevacizumab Generics Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Bevacizumab Generics Average Price by Manufacturers (2019-2024)
2.4 Global Key Players of Bevacizumab Generics, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Bevacizumab Generics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Bevacizumab Generics, Product Type & Application
2.7 Global Key Manufacturers of Bevacizumab Generics, Date of Enter into This Industry
2.8 Global Bevacizumab Generics Market Competitive Situation and Trends
2.8.1 Global Bevacizumab Generics Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Bevacizumab Generics Players Market Share by Revenue
2.8.3 Global Bevacizumab Generics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Bevacizumab Generics Market Scenario by Region
3.1 Global Bevacizumab Generics Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Bevacizumab Generics Sales by Region: 2019-2030
3.2.1 Global Bevacizumab Generics Sales by Region: 2019-2024
3.2.2 Global Bevacizumab Generics Sales by Region: 2025-2030
3.3 Global Bevacizumab Generics Revenue by Region: 2019-2030
3.3.1 Global Bevacizumab Generics Revenue by Region: 2019-2024
3.3.2 Global Bevacizumab Generics Revenue by Region: 2025-2030
3.4 North America Bevacizumab Generics Market Facts & Figures by Country
3.4.1 North America Bevacizumab Generics Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Bevacizumab Generics Sales by Country (2019-2030)
3.4.3 North America Bevacizumab Generics Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Bevacizumab Generics Market Facts & Figures by Country
3.5.1 Europe Bevacizumab Generics Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Bevacizumab Generics Sales by Country (2019-2030)
3.5.3 Europe Bevacizumab Generics Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Bevacizumab Generics Market Facts & Figures by Region
3.6.1 Asia Pacific Bevacizumab Generics Market Size by Region: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Bevacizumab Generics Sales by Region (2019-2030)
3.6.3 Asia Pacific Bevacizumab Generics Revenue by Region (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Bevacizumab Generics Market Facts & Figures by Country
3.7.1 Latin America Bevacizumab Generics Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Bevacizumab Generics Sales by Country (2019-2030)
3.7.3 Latin America Bevacizumab Generics Revenue by Country
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Bevacizumab Generics Market Facts & Figures by Country
3.8.1 Middle East and Africa Bevacizumab Generics Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Bevacizumab Generics Sales by Country (2019-2030)
3.8.3 Middle East and Africa Bevacizumab Generics Revenue by Country
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Bevacizumab Generics Sales by Type (2019-2030)
4.1.1 Global Bevacizumab Generics Sales by Type (2019-2024)
4.1.2 Global Bevacizumab Generics Sales by Type (2025-2030)
4.1.3 Global Bevacizumab Generics Sales Market Share by Type (2019-2030)
4.2 Global Bevacizumab Generics Revenue by Type (2019-2030)
4.2.1 Global Bevacizumab Generics Revenue by Type (2019-2024)
4.2.2 Global Bevacizumab Generics Revenue by Type (2025-2030)
4.2.3 Global Bevacizumab Generics Revenue Market Share by Type (2019-2030)
4.3 Global Bevacizumab Generics Price by Type (2019-2030)
5 Segment by Application
5.1 Global Bevacizumab Generics Sales by Application (2019-2030)
5.1.1 Global Bevacizumab Generics Sales by Application (2019-2024)
5.1.2 Global Bevacizumab Generics Sales by Application (2025-2030)
5.1.3 Global Bevacizumab Generics Sales Market Share by Application (2019-2030)
5.2 Global Bevacizumab Generics Revenue by Application (2019-2030)
5.2.1 Global Bevacizumab Generics Revenue by Application (2019-2024)
5.2.2 Global Bevacizumab Generics Revenue by Application (2025-2030)
5.2.3 Global Bevacizumab Generics Revenue Market Share by Application (2019-2030)
5.3 Global Bevacizumab Generics Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Amneal Pharmaceuticals
6.1.1 Amneal Pharmaceuticals Company Information
6.1.2 Amneal Pharmaceuticals Description and Business Overview
6.1.3 Amneal Pharmaceuticals Bevacizumab Generics Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Amneal Pharmaceuticals Bevacizumab Generics Product Portfolio
6.1.5 Amneal Pharmaceuticals Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Company Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Bevacizumab Generics Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Amgen Bevacizumab Generics Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Celltrion Healthcare
6.3.1 Celltrion Healthcare Company Information
6.3.2 Celltrion Healthcare Description and Business Overview
6.3.3 Celltrion Healthcare Bevacizumab Generics Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Celltrion Healthcare Bevacizumab Generics Product Portfolio
6.3.5 Celltrion Healthcare Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Bevacizumab Generics Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Pfizer Bevacizumab Generics Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Qilu Pharma
6.5.1 Qilu Pharma Company Information
6.5.2 Qilu Pharma Description and Business Overview
6.5.3 Qilu Pharma Bevacizumab Generics Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Qilu Pharma Bevacizumab Generics Product Portfolio
6.5.5 Qilu Pharma Recent Developments/Updates
6.6 Chia Tai Tianqing
6.6.1 Chia Tai Tianqing Company Information
6.6.2 Chia Tai Tianqing Description and Business Overview
6.6.3 Chia Tai Tianqing Bevacizumab Generics Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Chia Tai Tianqing Bevacizumab Generics Product Portfolio
6.6.5 Chia Tai Tianqing Recent Developments/Updates
6.7 Jiangsu Hengrui Pharmaceuticals
6.7.1 Jiangsu Hengrui Pharmaceuticals Company Information
6.7.2 Jiangsu Hengrui Pharmaceuticals Description and Business Overview
6.7.3 Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Sales, Revenue and Gross Margin (2019-2024)
6.7.4 Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Product Portfolio
6.7.5 Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
6.8 Innovent
6.8.1 Innovent Company Information
6.8.2 Innovent Description and Business Overview
6.8.3 Innovent Bevacizumab Generics Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Innovent Bevacizumab Generics Product Portfolio
6.8.5 Innovent Recent Developments/Updates
6.9 Bio-Thera Solutions
6.9.1 Bio-Thera Solutions Company Information
6.9.2 Bio-Thera Solutions Description and Business Overview
6.9.3 Bio-Thera Solutions Bevacizumab Generics Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Bio-Thera Solutions Bevacizumab Generics Product Portfolio
6.9.5 Bio-Thera Solutions Recent Developments/Updates
6.10 SinoCellTech
6.10.1 SinoCellTech Company Information
6.10.2 SinoCellTech Description and Business Overview
6.10.3 SinoCellTech Bevacizumab Generics Sales, Revenue and Gross Margin (2019-2024)
6.10.4 SinoCellTech Bevacizumab Generics Product Portfolio
6.10.5 SinoCellTech Recent Developments/Updates
6.11 Shanghai Henlius Biotech
6.11.1 Shanghai Henlius Biotech Company Information
6.11.2 Shanghai Henlius Biotech Description and Business Overview
6.11.3 Shanghai Henlius Biotech Bevacizumab Generics Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Shanghai Henlius Biotech Bevacizumab Generics Product Portfolio
6.11.5 Shanghai Henlius Biotech Recent Developments/Updates
6.12 Zhejiang Beta Pharma
6.12.1 Zhejiang Beta Pharma Company Information
6.12.2 Zhejiang Beta Pharma Description and Business Overview
6.12.3 Zhejiang Beta Pharma Bevacizumab Generics Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Zhejiang Beta Pharma Bevacizumab Generics Product Portfolio
6.12.5 Zhejiang Beta Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Bevacizumab Generics Industry Chain Analysis
7.2 Bevacizumab Generics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Bevacizumab Generics Production Mode & Process
7.4 Bevacizumab Generics Sales and Marketing
7.4.1 Bevacizumab Generics Sales Channels
7.4.2 Bevacizumab Generics Distributors
7.5 Bevacizumab Generics Customers
8 Bevacizumab Generics Market Dynamics
8.1 Bevacizumab Generics Industry Trends
8.2 Bevacizumab Generics Market Drivers
8.3 Bevacizumab Generics Market Challenges
8.4 Bevacizumab Generics Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
 Table 1. Global Bevacizumab Generics Market Value Comparison by Type (2024-2030) & (US$ Million)
 Table 2. Global Bevacizumab Generics Market Value by Application (2024-2030) & (US$ Million)
 Table 3. Global Bevacizumab Generics Market Competitive Situation by Manufacturers in 2023
 Table 4. Global Bevacizumab Generics Sales (K Dose) of Key Manufacturers (2019-2024)
 Table 5. Global Bevacizumab Generics Sales Market Share by Manufacturers (2019-2024)
 Table 6. Global Bevacizumab Generics Revenue (US$ Million) by Manufacturers (2019-2024)
 Table 7. Global Bevacizumab Generics Revenue Share by Manufacturers (2019-2024)
 Table 8. Global Market Bevacizumab Generics Average Price (US$/Dose) of Key Manufacturers (2019-2024)
 Table 9. Global Key Players of Bevacizumab Generics, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Bevacizumab Generics, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Bevacizumab Generics, Product Type & Application
 Table 12. Global Key Manufacturers of Bevacizumab Generics, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Bevacizumab Generics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bevacizumab Generics as of 2023)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Bevacizumab Generics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Table 17. Global Bevacizumab Generics Sales by Region (2019-2024) & (K Dose)
 Table 18. Global Bevacizumab Generics Sales Market Share by Region (2019-2024)
 Table 19. Global Bevacizumab Generics Sales by Region (2025-2030) & (K Dose)
 Table 20. Global Bevacizumab Generics Sales Market Share by Region (2025-2030)
 Table 21. Global Bevacizumab Generics Revenue by Region (2019-2024) & (US$ Million)
 Table 22. Global Bevacizumab Generics Revenue Market Share by Region (2019-2024)
 Table 23. Global Bevacizumab Generics Revenue by Region (2025-2030) & (US$ Million)
 Table 24. Global Bevacizumab Generics Revenue Market Share by Region (2025-2030)
 Table 25. North America Bevacizumab Generics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 26. North America Bevacizumab Generics Sales by Country (2019-2024) & (K Dose)
 Table 27. North America Bevacizumab Generics Sales by Country (2025-2030) & (K Dose)
 Table 28. North America Bevacizumab Generics Revenue by Country (2019-2024) & (US$ Million)
 Table 29. North America Bevacizumab Generics Revenue by Country (2025-2030) & (US$ Million)
 Table 30. Europe Bevacizumab Generics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 31. Europe Bevacizumab Generics Sales by Country (2019-2024) & (K Dose)
 Table 32. Europe Bevacizumab Generics Sales by Country (2025-2030) & (K Dose)
 Table 33. Europe Bevacizumab Generics Revenue by Country (2019-2024) & (US$ Million)
 Table 34. Europe Bevacizumab Generics Revenue by Country (2025-2030) & (US$ Million)
 Table 35. Asia Pacific Bevacizumab Generics Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
 Table 36. Asia Pacific Bevacizumab Generics Sales by Region (2019-2024) & (K Dose)
 Table 37. Asia Pacific Bevacizumab Generics Sales by Region (2025-2030) & (K Dose)
 Table 38. Asia Pacific Bevacizumab Generics Revenue by Region (2019-2024) & (US$ Million)
 Table 39. Asia Pacific Bevacizumab Generics Revenue by Region (2025-2030) & (US$ Million)
 Table 40. Latin America Bevacizumab Generics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 41. Latin America Bevacizumab Generics Sales by Country (2019-2024) & (K Dose)
 Table 42. Latin America Bevacizumab Generics Sales by Country (2025-2030) & (K Dose)
 Table 43. Latin America Bevacizumab Generics Revenue by Country (2019-2024) & (US$ Million)
 Table 44. Latin America Bevacizumab Generics Revenue Market Share by Country (2019-2024)
 Table 45. Middle East and Africa Bevacizumab Generics Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
 Table 46. Middle East and Africa Bevacizumab Generics Sales by Country (2019-2024) & (K Dose)
 Table 47. Middle East and Africa Bevacizumab Generics Sales by Country (2025-2030) & (K Dose)
 Table 48. Middle East and Africa Bevacizumab Generics Revenue by Country (2019-2024) & (US$ Million)
 Table 49. Middle East and Africa Bevacizumab Generics Revenue by Country (2025-2030) & (US$ Million)
 Table 50. Global Bevacizumab Generics Sales (K Dose) by Type (2019-2024)
 Table 51. Global Bevacizumab Generics Sales (K Dose) by Type (2025-2030)
 Table 52. Global Bevacizumab Generics Sales Market Share by Type (2019-2024)
 Table 53. Global Bevacizumab Generics Sales Market Share by Type (2025-2030)
 Table 54. Global Bevacizumab Generics Revenue (US$ Million) by Type (2019-2024)
 Table 55. Global Bevacizumab Generics Revenue (US$ Million) by Type (2025-2030)
 Table 56. Global Bevacizumab Generics Revenue Market Share by Type (2019-2024)
 Table 57. Global Bevacizumab Generics Revenue Market Share by Type (2025-2030)
 Table 58. Global Bevacizumab Generics Price (US$/Dose) by Type (2019-2024)
 Table 59. Global Bevacizumab Generics Price (US$/Dose) by Type (2025-2030)
 Table 60. Global Bevacizumab Generics Sales (K Dose) by Application (2019-2024)
 Table 61. Global Bevacizumab Generics Sales (K Dose) by Application (2025-2030)
 Table 62. Global Bevacizumab Generics Sales Market Share by Application (2019-2024)
 Table 63. Global Bevacizumab Generics Sales Market Share by Application (2025-2030)
 Table 64. Global Bevacizumab Generics Revenue (US$ Million) by Application (2019-2024)
 Table 65. Global Bevacizumab Generics Revenue (US$ Million) by Application (2025-2030)
 Table 66. Global Bevacizumab Generics Revenue Market Share by Application (2019-2024)
 Table 67. Global Bevacizumab Generics Revenue Market Share by Application (2025-2030)
 Table 68. Global Bevacizumab Generics Price (US$/Dose) by Application (2019-2024)
 Table 69. Global Bevacizumab Generics Price (US$/Dose) by Application (2025-2030)
 Table 70. Amneal Pharmaceuticals Company Information
 Table 71. Amneal Pharmaceuticals Description and Business Overview
 Table 72. Amneal Pharmaceuticals Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 73. Amneal Pharmaceuticals Bevacizumab Generics Product
 Table 74. Amneal Pharmaceuticals Recent Developments/Updates
 Table 75. Amgen Company Information
 Table 76. Amgen Description and Business Overview
 Table 77. Amgen Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 78. Amgen Bevacizumab Generics Product
 Table 79. Amgen Recent Developments/Updates
 Table 80. Celltrion Healthcare Company Information
 Table 81. Celltrion Healthcare Description and Business Overview
 Table 82. Celltrion Healthcare Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 83. Celltrion Healthcare Bevacizumab Generics Product
 Table 84. Celltrion Healthcare Recent Developments/Updates
 Table 85. Pfizer Company Information
 Table 86. Pfizer Description and Business Overview
 Table 87. Pfizer Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 88. Pfizer Bevacizumab Generics Product
 Table 89. Pfizer Recent Developments/Updates
 Table 90. Qilu Pharma Company Information
 Table 91. Qilu Pharma Description and Business Overview
 Table 92. Qilu Pharma Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 93. Qilu Pharma Bevacizumab Generics Product
 Table 94. Qilu Pharma Recent Developments/Updates
 Table 95. Chia Tai Tianqing Company Information
 Table 96. Chia Tai Tianqing Description and Business Overview
 Table 97. Chia Tai Tianqing Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 98. Chia Tai Tianqing Bevacizumab Generics Product
 Table 99. Chia Tai Tianqing Recent Developments/Updates
 Table 100. Jiangsu Hengrui Pharmaceuticals Company Information
 Table 101. Jiangsu Hengrui Pharmaceuticals Description and Business Overview
 Table 102. Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 103. Jiangsu Hengrui Pharmaceuticals Bevacizumab Generics Product
 Table 104. Jiangsu Hengrui Pharmaceuticals Recent Developments/Updates
 Table 105. Innovent Company Information
 Table 106. Innovent Description and Business Overview
 Table 107. Innovent Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 108. Innovent Bevacizumab Generics Product
 Table 109. Innovent Recent Developments/Updates
 Table 110. Bio-Thera Solutions Company Information
 Table 111. Bio-Thera Solutions Description and Business Overview
 Table 112. Bio-Thera Solutions Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 113. Bio-Thera Solutions Bevacizumab Generics Product
 Table 114. Bio-Thera Solutions Recent Developments/Updates
 Table 115. SinoCellTech Company Information
 Table 116. SinoCellTech Description and Business Overview
 Table 117. SinoCellTech Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 118. SinoCellTech Bevacizumab Generics Product
 Table 119. SinoCellTech Recent Developments/Updates
 Table 120. Shanghai Henlius Biotech Company Information
 Table 121. Shanghai Henlius Biotech Description and Business Overview
 Table 122. Shanghai Henlius Biotech Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 123. Shanghai Henlius Biotech Bevacizumab Generics Product
 Table 124. Shanghai Henlius Biotech Recent Developments/Updates
 Table 125. Zhejiang Beta Pharma Company Information
 Table 126. Zhejiang Beta Pharma Description and Business Overview
 Table 127. Zhejiang Beta Pharma Bevacizumab Generics Sales (K Dose), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2019-2024)
 Table 128. Zhejiang Beta Pharma Bevacizumab Generics Product
 Table 129. Zhejiang Beta Pharma Recent Developments/Updates
 Table 130. Key Raw Materials Lists
 Table 131. Raw Materials Key Suppliers Lists
 Table 132. Bevacizumab Generics Distributors List
 Table 133. Bevacizumab Generics Customers List
 Table 134. Bevacizumab Generics Market Trends
 Table 135. Bevacizumab Generics Market Drivers
 Table 136. Bevacizumab Generics Market Challenges
 Table 137. Bevacizumab Generics Market Restraints
 Table 138. Research Programs/Design for This Report
 Table 139. Key Data Information from Secondary Sources
 Table 140. Key Data Information from Primary Sources
 Table 141. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Bevacizumab Generics
 Figure 2. Global Bevacizumab Generics Market Value Comparison by Type (2024-2030) & (US$ Million)
 Figure 3. Global Bevacizumab Generics Market Share by Type: 2023 & 2030
 Figure 4. 100mg per Vial Product Picture
 Figure 5. 400mg per Vial Product Picture
 Figure 6. Global Bevacizumab Generics Market Value by Application (2024-2030) & (US$ Million)
 Figure 7. Global Bevacizumab Generics Market Share by Application: 2023 & 2030
 Figure 8. Hospital and Clinic
 Figure 9. Retail Pharmacies
 Figure 10. Other
 Figure 11. Global Bevacizumab Generics Revenue, (US$ Million), 2019 VS 2023 VS 2030
 Figure 12. Global Bevacizumab Generics Market Size (2019-2030) & (US$ Million)
 Figure 13. Global Bevacizumab Generics Sales (2019-2030) & (K Dose)
 Figure 14. Global Bevacizumab Generics Average Price (US$/Dose) & (2019-2030)
 Figure 15. Bevacizumab Generics Report Years Considered
 Figure 16. Bevacizumab Generics Sales Share by Manufacturers in 2023
 Figure 17. Global Bevacizumab Generics Revenue Share by Manufacturers in 2023
 Figure 18. Global 5 and 10 Largest Bevacizumab Generics Players: Market Share by Revenue in Bevacizumab Generics in 2023
 Figure 19. Bevacizumab Generics Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
 Figure 20. Global Bevacizumab Generics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
 Figure 21. North America Bevacizumab Generics Sales Market Share by Country (2019-2030)
 Figure 22. North America Bevacizumab Generics Revenue Market Share by Country (2019-2030)
 Figure 23. United States Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 24. Canada Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 25. Europe Bevacizumab Generics Sales Market Share by Country (2019-2030)
 Figure 26. Europe Bevacizumab Generics Revenue Market Share by Country (2019-2030)
 Figure 27. Germany Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 28. France Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 29. U.K. Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 30. Italy Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 31. Russia Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 32. Asia Pacific Bevacizumab Generics Sales Market Share by Region (2019-2030)
 Figure 33. Asia Pacific Bevacizumab Generics Revenue Market Share by Region (2019-2030)
 Figure 34. China Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 35. Japan Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 36. South Korea Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 37. India Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 38. Australia Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 39. China Taiwan Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 40. Southeast Asia Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 41. Latin America Bevacizumab Generics Sales Market Share by Country (2019-2030)
 Figure 42. Mexico Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 43. Brazil Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 44. Argentina Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 45. Colombia Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 46. Middle East and Africa Bevacizumab Generics Sales Market Share by Country (2019-2030)
 Figure 47. Middle East and Africa Bevacizumab Generics Revenue Market Share by Country (2019-2030)
 Figure 48. Turkey Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 49. Saudi Arabia Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 50. UAE Bevacizumab Generics Revenue Growth Rate (2019-2030) & (US$ Million)
 Figure 51. Global Sales Market Share of Bevacizumab Generics by Type (2019-2030)
 Figure 52. Global Revenue Market Share of Bevacizumab Generics by Type (2019-2030)
 Figure 53. Global Bevacizumab Generics Price (US$/Dose) by Type (2019-2030)
 Figure 54. Global Sales Market Share of Bevacizumab Generics by Application (2019-2030)
 Figure 55. Global Revenue Market Share of Bevacizumab Generics by Application (2019-2030)
 Figure 56. Global Bevacizumab Generics Price (US$/Dose) by Application (2019-2030)
 Figure 57. Bevacizumab Generics Value Chain
 Figure 58. Bevacizumab Generics Production Process
 Figure 59. Channels of Distribution (Direct Vs Distribution)
 Figure 60. Bottom-up and Top-down Approaches for This Report
 Figure 61. Data Triangulation
 Figure 62. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano Dimension